Safety of vedolizumab in liver transplant recipients: a systematic review
Open accessAbstract
Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno‐compromised patients. Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety. Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes. Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow‐up time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients. Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vedolizumab appears safe, with occasional reports of worsening serum liver tests that are not clearly related to the drug.
“Vedolizumab also appears safe, 420 with occasional reports of worsening serum liver tests that are not clearly related to the drug.”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [420]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · see citing works
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892 · see citing works
Self-citationInfection in Solid-Organ Transplant Recipients
Fishman, J. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra064928 · Cited by 1,950 · see citing works
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,217 · see citing works
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J., Sands, B. E., Rutgeerts, P. J., Sandborn, W. J., Danese, S., D’Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I. H., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 805 · see citing works
Self-citationClinical use of anti-TNF therapy and increased risk of infections
Ali, T., Bronze, Kaitha, Mahmood, Ftaisi, & Stone (2013) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s28801 · Cited by 244 · see citing works
Hildebrand, T., Pannicke, N., Dechene, A., Gotthardt, D. N., Kirchner, G., Reiter, F. P., Sterneck, M., Herzer, K., Lenzen, H., Rupp, C., et al. (2016) · Liver Transplantation · doi:10.1002/lt.24350 · Cited by 162 · see citing works
Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis
Singh, S., Loftus, E. V., & Talwalkar, J. A. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.163 · Cited by 97 · see citing works
Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14525 · Cited by 91 · see citing works
Tse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14829 · Cited by 76 · see citing works
Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis
Westerouen van Meeteren, M. J., Hayee, B., Inderson, A., van der Meulen, A. E., Altwegg, R., van Hoek, B., Pageaux, G. P., Stijnen, T., Stein, D., & Maljaars, P. W. J. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx057 · Cited by 39 · see citing works
Lim, T. Y., Pavlidis, P., Gulati, S., Pirani, T., Samaan, M., Chung‐Faye, G., Dubois, P. C. A., Irving, P. M., Heneghan, M. A., & Hayee, B. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000906 · Cited by 28 · see citing works
Wright, A. P., Fontana, R. J., & Stidham, R. W. (2017) · Liver Transplantation · doi:10.1002/lt.24757 · Cited by 20 · see citing works
Hartery, K., O’Reilly, S. M., Houlihan, D., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13861 · Cited by 15 · see citing works
Martín, R. V. O., Trillo, V. A., Grande, R. G., et al. (2017) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2017.5024/2017 · Cited by 10 · see citing works
Mumtaz, S., Goh, J., Hirschfield, G. M., et al. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2016-100711 · Cited by 7 · see citing works
Singh, A., Fritze, D. M., Mansouri, M., López, R., Poordad, F. F., Lawitz, E., Cigarroa, F. G., Halff, G. A., & Alkhouri, N. (2018) · Transplantation · doi:10.1097/tp.0000000000002501 · Cited by 6 · see citing works
Daffra, P. R., Etchevers, M. J., Sobrero, M. J., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx002.266 · Cited by 5 · see citing works
Peverelle, M., Mills, C. D., Testro, A., et al. (2018) · Gastroenterology · doi:10.1016/s0016-5085(18)32865-8 · Cited by 3 · see citing works
P501 Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
Drastich, P., Březina, J., Bajer, L., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx180.628 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419 · see citing works
- Authors
- Spadaccini, M., Aghemo, A., Caprioli, F., Lleo, A., Invernizzi, F., Danese, S., & Donato, M. F.
- Affiliations
- Humanitas University (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Department of Biomedical Sciences<!--<institution-id institution-id-type="Ringgold">437807</institution-id>--> Humanitas University Rozzano Italy
- Corresponding author
- Aghemo, Alessio
- ORCID
- Venue
- United European Gastroenterology Journal
- Publisher
- Wiley
- Published
- 2019-08
- Volume
- 7
- Issue
- 7
- Pages
- 875-880
- ISSN
- 2050-6406 (ISSN-L)
- 2050-6414
- PMC
- PMC6683639
- OpenAlex
- W2952461763
- Cited by
- 20
- References
- 20
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 2 · 2019: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- United European Gastroenterology Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- vedolizumab, liver transplantation, inflammatory bowel disease, drug safety, adverse events, infection, immunosuppression, biologic therapy, graft function
- MeSH terms
- Gastrointestinal Agents, Graft Rejection, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Liver Transplantation, Immunocompromised Host, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
